At-home PTCy	At-home non-PTCy	In-patient PTCy	Inpatient non-PTCy	2-sided p value
Patients (n)	7	8	6	5
Age (years)	31 (25-60)	53 (29-64)	45 (23-59)	50 (42-57)	0.58
Median HCT-CI	2 (0-4)	3 (0-4)	3 (0-3)	2 (0-3)	0.19
Diagnosis					0.99
AML/MDS	0 (0%)	1 (12.5%)	0 (0%)	1 (20%)
Lymphoma	6 (85.7%)	5 (62.5%)	5 (83.3%)	2 (40%)
MM	1 (14.3%)	2 (25%)	1 (16.7%)	2 (40%)
Donor					0.414
*Related	4 (57.1%)	5 (62.5%)	4 (66.7%)	1 (20%)
*Unrelated	3 (42.9%)	3 (37.5%)	2 (33.3%)	4 (80%)
HLA compatibility
*Identical	3 (42.9%)	8 (100%)	2 (33.3%)	5 (100%)	0.011
*Mismatched 7/8	1 (14.3%)	0 (0%)	1 (16.7%)	0 (0%)
*Haploidentical	3 (42.9%)	0 (0%)	3 (50%)	0 (0%)
CMV risk					0.93
Low	2 (28.6%)	3 (37.5%)	2 (33.3%)	1 (20%)
Intermediate	4 (57.1%)	4 (50%)	3 (50%)	3 (60%)
High	1 (14.3%)	1 (12.5%)	1 (16.7%)	1 (20%)
Conditioning regimen intensity
*MAC	0 (0%)	3 (37.5%)	1 (16.7%)	1 (20%)	0.35